MTCO2P9

Across TCGA pan-cancer cohorts, MTCO2P9 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated MTCO2P9 data layer.

The strongest signal is observed in breast invasive carcinoma (BRCA), where higher MTCO2P9 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated MTCO2P9 expression acts as an unfavorable survival marker, although some lineages such as BLCA show a favorable association.

BRCA, ESCA, and CESC are the cancer types where MTCO2P9 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
BRCA	OS	Tertile	II,III,IV	0.122	0.566	<.001	90	view →
ESCA	OS	Tertile	II,III,IV	0.103	0.868	<.001	54	view →
CESC	OS	Tertile	All	0.152	0.875	<.001	36	view →
UCEC	OS	Tertile	IV	0.308	0.748	.009	24	view →
LGG	DFS	Tertile	All	0.410	0.734	.013	12	view →
STAD	DFS	Tertile	All	0.350	0.566	.027	9	view →
THCA	DFS	Tertile	II,III,IV	0.161	0.732	.036	9	view →
BLCA	OS	Tertile	II,III,IV	1.000	0.411	.048	6	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

MTCO2P9–BRCA (OS)

Open the BRCA breakdown →